- CRS Publications
- News
News
Date:
PRNewswire: March 23, 2017 – BOSTON, MA, U.S.A. – Newborns are highly vulnerable to infections and don’t respond optimally to most vaccines because their young immune systems typically mount weak antibody responses. Now, researchers at Boston Children’s Hospital report achieving strong vaccine…
Authors:
Date:
PRNewswire: March 22, 2017 – JERUSALEM, Israel – Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a phase I clinical trial of AP-CBD/THC, its…
Authors:
Date:
PRNewswire: March 21, 2017 – NEW YORK, NY, U.S.A. and SYDNEY, Australia – EnGeneIC Limited today announced that it has begun dosing patients in a U.S.-based open-label phase 1 clinical trial evaluating its proprietary EDV™ nanocells to treat recurrent glioblastoma multiforme (GBM) in adults.
GBM…
Authors:
Date:
PRNewswire: March 21, 2017 – LEXINGTON, MA, U.S.A. – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key patent from the European Union.
“This new patent…
Authors:
Date:
PRNewswire: March 21, 2017 – MISSISSAUGA, ON, Canada – Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the company), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases…
Authors:
Date:
Business Wire: March 20, 2017 – HEIDELBERG, Germany – Novaliq, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced a strategic licensing agreement with AFT Pharmaceuticals (…
